| |
|
|
|
|
|
|
|
Oncology |
|
|
|
|
|
| Rank |
|
2002 |
|
Rank |
|
2003 |
|
Rank |
|
2004 |
|
Rank |
|
2005 |
| |
|
Impact |
|
|
|
Impact |
|
|
|
Impact |
|
|
|
Impact |
| 1 |
CA-CANCER J CLIN |
32.89 |
|
1 |
NAT REV CANCER |
33.95 |
|
1 |
CA-CANCER J CLIN |
44.52 |
|
1 |
CA-CANCER J CLIN |
49.8 |
| 2 |
J NATL CANCER I |
14.5 |
|
2 |
CA-CANCER J CLIN |
33.06 |
|
2 |
NAT REV CANCER |
36.56 |
|
2 |
NAT REV CANCER |
31.7 |
| 3 |
NAT REV CANCER |
13.63 |
|
3 |
CANCER CELL |
18.91 |
|
3 |
CANCER CELL |
18.12 |
|
3 |
CANCER CELL |
18.7 |
| 4 |
J CLIN ONCOL |
9.868 |
|
4 |
J NATL CANCER I |
13.84 |
|
4 |
BBA-REV CANCER |
16.12 |
|
4 |
J NATL CANCER I |
15.2 |
| 5 |
ADV CANCER RES |
9.778 |
|
5 |
J CLIN ONCOL |
10.86 |
|
5 |
J NATL CANCER I |
13.86 |
|
5 |
BBA-REV CANCER |
12.1 |
| 6 |
BBA-REV CANCER |
9.351 |
|
6 |
ENDOCR-RELAT CANCER |
8.894 |
|
6 |
J CLIN ONCOL |
9.835 |
|
6 |
J CLIN ONCOL |
11.8 |
| 7 |
CANCER RES |
8.318 |
|
7 |
CANCER RES |
8.649 |
|
7 |
EJC SUPPL |
9.023 |
|
7 |
CANCER METAST REV |
8.02 |
| 8 |
ENDOCR-RELAT CANCER |
6.087 |
|
8 |
BBA-REV CANCER |
8.395 |
|
8 |
LANCET ONCOL |
8.794 |
|
8 |
SEMIN CANCER BIOL |
7.99 |
| 9 |
CLIN CANCER RES |
5.991 |
|
9 |
ADV CANCER RES |
7.938 |
|
9 |
CANCER RES |
7.69 |
|
9 |
ADV CANCER RES |
7.91 |
| 10 |
ONCOGENE |
5.979 |
|
10 |
LANCET ONCOL |
7.411 |
|
10 |
SEMIN CANCER BIOL |
7.644 |
|
10 |
LANCET ONCOL |
7.86 |
| 11 |
NEOPLASIA |
5.917 |
|
11 |
CLIN CANCER RES |
6.511 |
|
11 |
ONCOGENE |
6.318 |
|
11 |
CANCER RES |
7.62 |
| 12 |
SEMIN CANCER BIOL |
5.685 |
|
12 |
ONCOGENE |
6.495 |
|
12 |
ADV CANCER RES |
6.2 |
|
12 |
ONCOGENE |
6.87 |
| 13 |
CARCINOGENESIS |
5.405 |
|
13 |
STEM CELLS |
5.802 |
|
13 |
LEUKEMIA |
5.81 |
|
13 |
LEUKEMIA |
6.61 |
| 14 |
CANCER EPIDEM BIOMAR |
5.14 |
|
14 |
SEMIN CANCER BIOL |
5.495 |
|
14 |
CLIN CANCER RES |
5.623 |
|
14 |
STEM CELLS |
6.09 |
| 15 |
EXP CELL RES |
4.712 |
|
15 |
LEUKEMIA |
5.116 |
|
15 |
STEM CELLS |
5.5 |
|
15 |
CLIN CANCER RES |
5.72 |
| 16 |
LEUKEMIA |
4.693 |
|
16 |
SEMIN ONCOL |
4.733 |
|
16 |
CARCINOGENESIS |
5.375 |
|
16 |
MOL CANCER RES |
5.42 |
| 17 |
CURR OPIN ONCOL |
4.275 |
|
17 |
CANCER EPIDEM BIOMAR |
4.72 |
|
17 |
MOL CANCER THER |
5.242 |
|
17 |
MOL CANCER THER |
5.17 |
| 18 |
GENE CHROMOSOME CANC |
4.199 |
|
18 |
CARCINOGENESIS |
4.663 |
|
18 |
MOL CANCER RES |
4.813 |
|
18 |
ONCOLOGIST |
5.13 |
| 19 |
INT J CANCER |
4.056 |
|
19 |
CURR OPIN ONCOL |
4.544 |
|
19 |
ONCOLOGIST |
4.623 |
|
19 |
CARCINOGENESIS |
5.11 |
| 20 |
STEM CELLS |
4.034 |
|
20 |
INT J CANCER |
4.375 |
|
20 |
ENDOCR-RELAT CANCER |
4.597 |
|
20 |
ENDOCR-RELAT CANCER |
4.91 |
| 21 |
CANCER |
3.941 |
|
21 |
NEOPLASIA |
4.312 |
|
21 |
CANCER EPIDEM BIOMAR |
4.5 |
|
21 |
CANCER |
4.8 |
| 22 |
ANN SURG ONCOL |
3.824 |
|
22 |
INT J RADIAT ONCOL |
4.285 |
|
22 |
CANCER |
4.434 |
|
22 |
INT J CANCER |
4.7 |
| 23 |
INT J RADIAT ONCOL |
3.756 |
|
23 |
GENE CHROMOSOME CANC |
4.192 |
|
23 |
INT J CANCER |
4.416 |
|
23 |
BREAST CANCER RES TR |
4.64 |
| 24 |
CANCER TREAT REV |
3.672 |
|
24 |
CANCER |
4.017 |
|
24 |
NEOPLASIA |
4.377 |
|
24 |
INT J RADIAT ONCOL |
4.56 |
| 25 |
BRIT J CANCER |
3.639 |
|
25 |
J IMMUNOTHER |
3.983 |
|
25 |
ANN ONCOL |
4.335 |
|
25 |
CANCER TREAT REV |
4.55 |
| 26 |
EUR J CANCER |
3.562 |
|
26 |
ONCOLOGIST |
3.962 |
|
26 |
INT J RADIAT ONCOL |
4.297 |
|
26 |
CANCER EPIDEM BIOMAR |
4.46 |
| 27 |
SEMIN ONCOL |
3.5 |
|
27 |
EXP CELL RES |
3.949 |
|
27 |
GENE CHROMOSOME CANC |
4.276 |
|
27 |
ANN ONCOL |
4.32 |
| 28 |
BREAST CANCER RES TR |
3.132 |
|
28 |
BRIT J CANCER |
3.894 |
|
28 |
ANN SURG ONCOL |
4.035 |
|
28 |
PROG EXP TUMOR RES |
4.21 |
| 29 |
ANN ONCOL |
3.114 |
|
29 |
EUR J CANCER |
3.694 |
|
29 |
EXP CELL RES |
4.007 |
|
29 |
CELL ONCOL |
4.16 |
| 30 |
J IMMUNOTHER |
3.107 |
|
30 |
CANCER GENE THER |
3.688 |
|
30 |
CURR OPIN ONCOL |
3.991 |
|
30 |
NEURO-ONCOLOGY |
4.15 |
| 31 |
INT J ONCOL |
2.931 |
|
31 |
ANN ONCOL |
3.605 |
|
31 |
SEMIN ONCOL |
3.98 |
|
31 |
EXP CELL RES |
4.15 |
| 32 |
CANCER GENE THER |
2.929 |
|
32 |
SEMIN RADIAT ONCOL |
3.604 |
|
32 |
NEURO-ONCOLOGY |
3.907 |
|
32 |
BRIT J CANCER |
4.12 |
| 33 |
CANCER CAUSE CONTROL |
2.896 |
|
33 |
ANN SURG ONCOL |
3.574 |
|
33 |
BRIT J CANCER |
3.742 |
|
33 |
CANCER IMMUNOL IMMUN |
4.09 |
| 34 |
INVEST NEW DRUG |
2.842 |
|
34 |
NEURO-ONCOLOGY |
3.365 |
|
34 |
CANCER GENE THER |
3.653 |
|
34 |
BREAST CANCER RES |
4.03 |
| 35 |
STRAHLENTHER ONKOL |
2.84 |
|
35 |
MOL CANCER THER |
3.201 |
|
35 |
PROG EXP TUMOR RES |
3.571 |
|
35 |
GENE CHROMOSOME CANC |
3.94 |
| 36 |
RADIOTHER ONCOL |
2.838 |
|
36 |
CANCER IMMUNOL IMMUN |
3.13 |
|
36 |
CANCER IMMUNOL IMMUN |
3.52 |
|
36 |
NEOPLASIA |
3.85 |
| 37 |
MOL CARCINOGEN |
2.821 |
|
37 |
HEMATOL ONCOL |
3.105 |
|
37 |
CANCER TREAT REV |
3.515 |
|
37 |
CANCER SCI |
3.83 |
| 38 |
BREAST CANCER RES |
2.817 |
|
38 |
CANCER BIOL THER |
3.024 |
|
38 |
J IMMUNOTHER |
3.509 |
|
38 |
EUR J CANCER |
3.71 |
| 39 |
CANCER IMMUNOL IMMUN |
2.759 |
|
39 |
CRIT REV ONCOL HEMAT |
2.979 |
|
39 |
BREAST CANCER RES TR |
3.31 |
|
39 |
SEMIN RADIAT ONCOL |
3.68 |
| 40 |
CRIT REV ONCOL HEMAT |
2.758 |
|
40 |
CANCER TREAT REV |
2.969 |
|
40 |
EUR J CANCER |
3.302 |
|
40 |
J IMMUNOTHER |
3.64 |
| 41 |
NEURO-ONCOLOGY |
2.717 |
|
41 |
BREAST CANCER RES TR |
2.964 |
|
41 |
CANCER BIOL THER |
3.279 |
|
41 |
SEMIN ONCOL |
3.63 |
| 42 |
SEMIN RADIAT ONCOL |
2.638 |
|
42 |
CANCER J |
2.955 |
|
42 |
CANCER METAST REV |
3.153 |
|
42 |
STRAHLENTHER ONKOL |
3.49 |
| 43 |
LUNG CANCER-J IASLC |
2.451 |
|
43 |
BREAST CANCER RES |
2.932 |
|
43 |
STRAHLENTHER ONKOL |
3.121 |
|
43 |
ANN SURG ONCOL |
3.46 |
| 44 |
CANCER J |
2.422 |
|
44 |
RADIOTHER ONCOL |
2.87 |
|
44 |
INT J ONCOL |
3.056 |
|
44 |
EJC SUPPL |
3.39 |
| 45 |
BONE MARROW TRANSPL |
2.378 |
|
45 |
MOL CARCINOGEN |
2.806 |
|
45 |
CLIN EXP METASTAS |
3.048 |
|
45 |
RADIOTHER ONCOL |
3.3 |
| 46 |
CANCER LETT |
2.346 |
|
46 |
CANCER CAUSE CONTROL |
2.726 |
|
46 |
RADIOTHER ONCOL |
3.034 |
|
46 |
CURR OPIN ONCOL |
3.26 |
| 47 |
ONCOLOGY-BASEL |
2.33 |
|
47 |
STRAHLENTHER ONKOL |
2.634 |
|
47 |
MOL CARCINOGEN |
3 |
|
47 |
CANCER CAUSE CONTROL |
3.2 |
| 48 |
CANCER METAST REV |
2.215 |
|
48 |
CANCER LETT |
2.614 |
|
48 |
BREAST CANCER RES |
2.975 |
|
48 |
EUR J SURG ONCOL |
3.18 |
| 49 |
J CANCER RES CLIN |
2.197 |
|
49 |
INT J ONCOL |
2.536 |
|
49 |
CANCER LETT |
2.938 |
|
49 |
LUNG CANCER-J IASLC |
3.17 |
| 50 |
MOL CANCER THER |
2.188 |
|
50 |
TUMOR BIOL |
2.518 |
|
50 |
LUNG CANCER-J IASLC |
2.914 |
|
50 |
CANCER LETT |
3.05 |
| 51 |
NUTR CANCER |
2.164 |
|
51 |
ACTA ONCOL |
2.46 |
|
51 |
SEMIN RADIAT ONCOL |
2.899 |
|
51 |
CANCER GENE THER |
3 |
| 52 |
GYNECOL ONCOL |
2.115 |
|
52 |
ONCOLOGY-BASEL |
2.381 |
|
52 |
CANCER CAUSE CONTROL |
2.847 |
|
52 |
CANCER BIOL THER |
2.98 |
| 52 |
LEUKEMIA RES |
2.115 |
|
53 |
GYNECOL ONCOL |
2.341 |
|
53 |
CRIT REV ONCOL HEMAT |
2.667 |
|
53 |
CRIT REV ONCOL HEMAT |
2.96 |
| 54 |
HEMATOL ONCOL CLIN N |
2.096 |
|
54 |
CURR PROB CANCER |
2.333 |
|
54 |
CANCER SCI |
2.652 |
|
54 |
CLIN EXP METASTAS |
2.81 |
| 55 |
CLIN EXP METASTAS |
2.08 |
|
54 |
LEUKEMIA RES |
2.333 |
|
55 |
J ENVIRON SCI HEAL C |
2.571 |
|
55 |
INT J ONCOL |
2.68 |
| 56 |
SEMIN SURG ONCOL |
2.05 |
|
56 |
BIODRUGS |
2.277 |
|
56 |
CANCER J |
2.513 |
|
56 |
BONE MARROW TRANSPL |
2.64 |
| 57 |
ANTI-CANCER DRUG |
2.013 |
|
57 |
INVEST NEW DRUG |
2.272 |
|
57 |
J CANCER RES CLIN |
2.409 |
|
57 |
CANCER J |
2.51 |
| 58 |
CANCER CHEMOTH PHARM |
1.928 |
|
58 |
MELANOMA RES |
2.19 |
|
58 |
HEMATOL ONCOL |
2.393 |
|
58 |
J CANCER RES CLIN |
2.5 |
| 59 |
JPN J CANCER RES |
1.918 |
|
59 |
CLIN LYMPHOMA |
2.184 |
|
59 |
TUMOR BIOL |
2.347 |
|
59 |
NUTR CANCER |
2.43 |
| 60 |
ACTA ONCOL |
1.909 |
|
60 |
BONE MARROW TRANSPL |
2.172 |
|
60 |
BMC CANCER |
2.29 |
|
60 |
INVEST NEW DRUG |
2.42 |
| 61 |
ORAL ONCOL |
1.873 |
|
61 |
J CANCER RES CLIN |
2.162 |
|
61 |
LEUKEMIA RES |
2.244 |
|
61 |
LEUKEMIA RES |
2.37 |
| 62 |
CANCER INVEST |
1.85 |
|
62 |
MOL CANCER RES |
2.125 |
|
62 |
JPN J CANCER RES |
2.225 |
|
62 |
MOL CARCINOGEN |
2.37 |
| 63 |
INT J HYPERTHER |
1.841 |
|
63 |
CANCER INVEST |
2.066 |
|
63 |
CANCER CHEMOTH PHARM |
2.216 |
|
63 |
ACTA ONCOL |
2.36 |
| 64 |
ANTI-CANCER DRUG DES |
1.815 |
|
64 |
ANTI-CANCER DRUG DES |
2.061 |
|
64 |
NUTR CANCER |
2.149 |
|
64 |
J NEURO-ONCOL |
2.33 |
| 65 |
MELANOMA RES |
1.773 |
|
65 |
CANCER CHEMOTH PHARM |
2.046 |
|
65 |
ONCOLOGY-BASEL |
2.114 |
|
65 |
PSYCHO-ONCOL |
2.32 |
| 66 |
CANCER GENET CYTOGEN |
1.713 |
|
66 |
CANCER CYTOPATHOL |
2.045 |
|
66 |
BONE MARROW TRANSPL |
2.101 |
|
66 |
ORAL ONCOL |
2.27 |
| 67 |
CANCER BIOTHER RADIO |
1.691 |
|
67 |
J SURG ONCOL |
1.991 |
|
67 |
GYNECOL ONCOL |
2.083 |
|
67 |
GYNECOL ONCOL |
2.25 |
| 68 |
EUR J CANCER PREV |
1.685 |
|
68 |
CANCER METAST REV |
1.982 |
|
68 |
PSYCHO-ONCOL |
2.079 |
|
68 |
CANCER CHEMOTH PHARM |
2.24 |
| 69 |
PSYCHO-ONCOL |
1.67 |
|
69 |
NUTR CANCER |
1.972 |
|
69 |
ANTI-CANCER DRUG |
2.052 |
|
69 |
CANCER CYTOPATHOL |
2.16 |
| 70 |
CANCER CYTOPATHOL |
1.66 |
|
70 |
CLIN EXP METASTAS |
1.944 |
|
70 |
ORAL ONCOL |
2 |
|
70 |
SURG ONCOL |
2.15 |
| 71 |
HEMATOL ONCOL |
1.65 |
|
71 |
ANTI-CANCER DRUG |
1.938 |
|
71 |
J NEURO-ONCOL |
1.968 |
|
71 |
BMC CANCER |
1.99 |
| 72 |
INT J BIOL MARKER |
1.571 |
|
72 |
ORAL ONCOL |
1.876 |
|
72 |
CANCER INVEST |
1.935 |
|
72 |
ONCOLOGY-BASEL |
1.99 |
| 73 |
J SURG ONCOL |
1.502 |
|
73 |
EUR J SURG ONCOL |
1.865 |
|
73 |
BIODRUGS |
1.905 |
|
73 |
J ENVIRON SCI HEAL C |
1.91 |
| 74 |
TUMOR BIOL |
1.489 |
|
74 |
PSYCHO-ONCOL |
1.859 |
|
74 |
INT J HYPERTHER |
1.888 |
|
74 |
ANTI-CANCER DRUG |
1.91 |
| 75 |
ONCOL RES |
1.476 |
|
75 |
CANCER BIOTHER RADIO |
1.841 |
|
75 |
ACTA ONCOL |
1.884 |
|
75 |
HEMATOL ONCOL CLIN N |
1.85 |
| 76 |
ANTICANCER RES |
1.447 |
|
76 |
LUNG CANCER-J IASLC |
1.798 |
|
76 |
EUR J SURG ONCOL |
1.882 |
|
76 |
CANCER INVEST |
1.85 |
| 76 |
MED ONCOL |
1.447 |
|
77 |
ONCOL RES |
1.794 |
|
77 |
INVEST NEW DRUG |
1.854 |
|
77 |
ONCOL RES |
1.84 |
| 78 |
J NEURO-ONCOL |
1.416 |
|
78 |
INT J HYPERTHER |
1.762 |
|
78 |
ONCOL RES |
1.844 |
|
78 |
CLIN LYMPHOMA |
1.84 |
| 79 |
EUR J SURG ONCOL |
1.392 |
|
79 |
MED PEDIATR ONCOL |
1.737 |
|
79 |
EUR J CANCER PREV |
1.785 |
|
79 |
J SURG ONCOL |
1.78 |
| 80 |
ONCOLOGY-NY |
1.336 |
|
80 |
SURG ONCOL |
1.725 |
|
80 |
CLIN LYMPHOMA |
1.758 |
|
80 |
HEMATOL ONCOL |
1.77 |
| 81 |
LEUKEMIA LYMPHOMA |
1.335 |
|
81 |
BMC CANCER |
1.702 |
|
80 |
J SURG ONCOL |
1.758 |
|
81 |
EUR J CANCER PREV |
1.76 |
| 82 |
SURG ONCOL |
1.314 |
|
82 |
EUR J CANCER PREV |
1.673 |
|
82 |
MELANOMA RES |
1.735 |
|
82 |
INT J HYPERTHER |
1.74 |
| 83 |
SUPPORT CARE CANCER |
1.299 |
|
83 |
JPN J CANCER RES |
1.624 |
|
83 |
SURG ONCOL |
1.709 |
|
83 |
BIODRUGS |
1.72 |
| 84 |
CANCER DETECT PREV |
1.289 |
|
84 |
J NEURO-ONCOL |
1.568 |
|
84 |
AM J CLIN ONCOL-CANC |
1.703 |
|
84 |
BREAST |
1.71 |
| 85 |
BIODRUGS |
1.245 |
|
85 |
INT J GYNECOL CANCER |
1.561 |
|
85 |
CANCER CYTOPATHOL |
1.654 |
|
85 |
TECHNOL CANCER RES T |
1.68 |
| 86 |
J PEDIAT HEMATOL ONC |
1.23 |
|
86 |
CANCER GENET CYTOGEN |
1.542 |
|
86 |
CANCER GENET CYTOGEN |
1.577 |
|
86 |
CANCER BIOTHER RADIO |
1.67 |
| 87 |
MED PEDIATR ONCOL |
1.216 |
|
87 |
J PEDIAT HEMATOL ONC |
1.463 |
|
87 |
CANCER PRACT |
1.553 |
|
87 |
MED PEDIATR ONCOL |
1.65 |
| 88 |
TERATOGEN CARCIN MUT |
1.189 |
|
88 |
ONCOLOGY-NY |
1.427 |
|
88 |
HEMATOL ONCOL CLIN N |
1.434 |
|
88 |
CANCER GENET CYTOGEN |
1.64 |
| 89 |
ONCOL REP |
1.171 |
|
89 |
AM J CLIN ONCOL-CANC |
1.369 |
|
89 |
CANCER DETECT PREV |
1.408 |
|
89 |
AM J CLIN ONCOL-CANC |
1.62 |
| 90 |
AM J CLIN ONCOL-CANC |
1.136 |
|
90 |
SUPPORT CARE CANCER |
1.367 |
|
90 |
ANTICANCER RES |
1.395 |
|
90 |
ANTICANCER RES |
1.6 |
| 91 |
BMC CANCER |
1.05 |
|
91 |
ANTICANCER RES |
1.347 |
|
91 |
UROL ONCOL-SEMIN ORI |
1.378 |
|
91 |
CANCER DETECT PREV |
1.6 |
| 92 |
INT J GYNECOL CANCER |
1.021 |
|
92 |
HEMATOL ONCOL CLIN N |
1.267 |
|
92 |
MED PEDIATR ONCOL |
1.362 |
|
92 |
SUPPORT CARE CANCER |
1.59 |
| |
|
|
|
93 |
ONCOL REP |
1.256 |
|
93 |
SUPPORT CARE CANCER |
1.36 |
|
93 |
ONCOL REP |
1.57 |
| |
|
|
|
94 |
CHEMOTHERAPY |
1.184 |
|
94 |
ONCOL REP |
1.356 |
|
94 |
MELANOMA RES |
1.53 |
| |
|
|
|
95 |
CANCER DETECT PREV |
1.18 |
|
95 |
ONKOLOGIE |
1.283 |
|
95 |
PEDIATR BLOOD CANCER |
1.51 |
| |
|
|
|
96 |
UROL ONCOL-SEMIN ORI |
1.167 |
|
96 |
CHEMOTHERAPY |
1.248 |
|
96 |
INT J GYNECOL CANCER |
1.43 |
| |
|
|
|
97 |
LEUKEMIA LYMPHOMA |
1.163 |
|
97 |
J PEDIAT HEMATOL ONC |
1.161 |
|
97 |
CHEMOTHERAPY |
1.41 |
| |
|
|
|
98 |
MED ONCOL |
1.159 |
|
98 |
MED ONCOL |
1.159 |
|
98 |
JPN J CLIN ONCOL |
1.32 |
| |
|
|
|
99 |
ONKOLOGIE |
1.154 |
|
99 |
INT J GYNECOL CANCER |
1.147 |
|
99 |
LEUKEMIA LYMPHOMA |
1.3 |
| |
|
|
|
100 |
INT J BIOL MARKER |
1.092 |
|
100 |
LEUKEMIA LYMPHOMA |
1.147 |
|
100 |
CLIN ONCOL-UK |
1.29 |
| |
|
|
|
101 |
J CHEMOTHERAPY |
1.088 |
|
101 |
PROSTATE CANCER P D |
1.144 |
|
101 |
J PEDIAT HEMATOL ONC |
1.28 |
| |
|
|
|
|
|
|
|
102 |
J CHEMOTHERAPY |
1.104 |
|
102 |
TUMOR BIOL |
1.24 |
| |
|
|
|
|
|
|
|
103 |
CANCER BIOTHER RADIO |
1.091 |
|
103 |
ONKOLOGIE |
1.21 |
| |
|
|
|
|
|
|
|
104 |
CANCER NURS |
1.079 |
|
104 |
BIRTH DEFECTS RES B |
1.21 |
| |
|
|
|
|
|
|
|
105 |
CURR PROB CANCER |
1.077 |
|
105 |
PATHOL ONCOL RES |
1.16 |
| |
|
|
|
|
|
|
|
106 |
BIRTH DEFECTS RES B |
1 |
|
106 |
J CHEMOTHERAPY |
1.15 |
| |
|
|
|
|
|
|
|
|
|
|
|
107 |
PROSTATE CANCER P D |
1.14 |
| |
|
|
|
|
|
|
|
|
|
|
|
108 |
INT J BIOL MARKER |
1.1 |
| |
|
|
|
|
|
|
|
|
|
|
|
109 |
UROL ONCOL-SEMIN ORI |
1.07 |
| |
|
|
|
|
|
|
|
|
|
|
|
110 |
EJSO |
1 |
| |
|
|
|
|
|
|
|
|
|
|
|
110 |
MED ONCOL |
1 |
|